Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Liuzhou LMZ Co., Ltd.
EIR
•Liuzhou LMZ Co., Ltd.•July 5, 2019

Liuzhou LMZ Co., Ltd. – FDA EIR, Jul 5, 2019

Record Details

An FDA inspection of Liuzhou LMZ Co., Ltd., a manufacturer of over-the-counter drugs including LMZ DR Gingiva Fluoride Toothpaste, was conducted from July 1 to July 5, 2019. This initial Good Manufacturing Practice (GMP) inspection identified significant deficiencies across various operational systems. The inspection was performed under Compliance Program 7356.002, Drug Manufacturing Inspections, which governs human OTC drug manufacturers. The main issues, documented on an FDA Form 483, included the company's failure to establish adequate written procedures for equipment maintenance, product stability studies, and environmental monitoring. The inspection also found that growth media used for microbiological testing was not subjected to required growth promotion tests, impacting the reliability of quality control. Furthermore, laboratory controls were deficient, lacking a comprehensive bulk hold time study for the US-marketed product and failing to adhere to proper water testing methods. Data integrity concerns arose from the absence of a second person review for critical laboratory raw data and equipment calibration records. Production areas showed equipment cleaning issues, with visible residues in dispensing stations, posing contamination risks. Finally, batch records lacked essential calculations for theoretical and actual product yields, hindering process control. The inspection was classified as Voluntary Action Indicated (VAI). Company President, Mr. Kun Wu, committed to submitting a written response to the FDA within 15 business days, outlining corrective actions to address these observed deviations from regulatory standards.

Company
Liuzhou LMZ Co., Ltd.
Inspection date
July 5, 2019
Product type
OTC (Over-the-Counter)
Office
Office of Regulatory Affairs
People
  • Zhongren Wu (Principal Consultant)
  • Valerie L. Whipp (issuing_officer)
View Company Profile

ID · b2112318-0fb3-400a-ad2c-5663c9552f35

Violation Codes8
21 CFR 211.160(b)21 CFR 211.194(a)(2)21 CFR 21121 CFR 211.67(a)21 CFR 211.194(a)(8)21 CFR 820.10021 CFR 211.188(b)(7)21 CFR 211.22(d)

Full citation text and observation details available on the Dashboard.

Other documents for Liuzhou LMZ Co., Ltd.
  • 483 - 2019-07-05July 5, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Liuzhou LMZ Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.